Home Newsfeeds Benchmark Downgrades Invitae to Hold

Benchmark Downgrades Invitae to Hold

Benchmark analyst Bruce Jackson downgrades Invitae (NYSE:NVTA) from Buy to Hold.

byBenzinga Newsdesk

July 19, 2022

1 minute read

Benchmark analyst Bruce Jackson downgrades Invitae (NYSE:NVTA) from Buy to Hold.

SVB Leerink Maintains Outperform on Mereo BioPharma Group, Lowers Price Target to $4

By Benzinga Newsdesk

November 10, 4:54 AM

SVB Leerink analyst Joseph Schwartz maintains Mereo BioPharma Group (NASDAQ:MREO) with a Outperform and lowers the price target from $8 to $4.

MREO

Morgan Stanley Maintains Underweight on Southern, Lowers Price Target to $68

By Benzinga Newsdesk

September 22, 10:53 AM

Morgan Stanley analyst Stephen Byrd maintains Southern (NYSE:SO) with a Underweight and lowers the price target from $69 to $68.

Nasdaq Surges Over 100 Points; G Medical Innovations Shares Plunge

By Lisa Levin

March 31, 12:02 PM

U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 100 points on Friday. The Dow traded up 0.69% to 33,086.43 while the NASDAQ rose 1.01% to 12,134.43. The S&P 500, also rose, gaining, 0.78% to 4,082.51.

CSSE

News

SentinelOne Achieves 100% Prevention And Detection In MITRE Engenuity ATT&CK Evaluation

By Benzinga Newsdesk

September 20, 9:05 AM

Singularity™ XDR provides real-time protection with zero delays or configuration changesSentinelOne (NYSE:S), a global leader in autonomous cybersecurity, released its results from the fifth round of MITRE

Benchmark Downgrades Invitae to Hold

Related Posts

SVB Leerink Maintains Outperform on Mereo BioPharma Group, Lowers Price Target to $4

Morgan Stanley Maintains Underweight on Southern, Lowers Price Target to $68

Nasdaq Surges Over 100 Points; G Medical Innovations Shares Plunge

SentinelOne Achieves 100% Prevention And Detection In MITRE Engenuity ATT&CK Evaluation